Electrical Impedance Tomography, Thoracic Breath Sensor and Lung Ultrasound measurements of Neonates with Respiratory Distress Syndrome during surfactant administration

Mater Health0 sites40 target enrollmentMarch 10, 2020

Overview

No summary available.

Registry

who.int

Start Date

March 10, 2020

End Date

TBD

Last Updated

6 years ago

Study Type

Interventional

Sex

All

Sponsor

Mater Health

•Infants 26 0/7 to 31 6/7 weeks corrected gestational age (gestation at birth plus days since birth)
•Weight appropriate for gestational age at birth
•Age \< 72 hours
•Currently on nCPAP with an FiO2 requirement \<0\.30
•Approval of treating medical and nursing staff for recruitment to relevant study arm
•Parent(s) or guardian able and willing to provide informed consent
•At least one parent or guardian aged 18 years or older at the time of consent
•Have not yet received a dose of surfactant

•Apgar score less than or equal to 5 at five minutes after birth
•Both parents of baby under 18 years of age (due to the complexities of obtaining consent).
•Prior instillation of surfactant
•Congenital anomaly or syndrome expected to have significant effect on cardio\-respiratory function
•Other diseases interfering with cardiopulmonary functions (hydrops fetalis, toxoplasmosis, rubella, cytomegalovirus, herpes simplex)
•Known or suspected chromosomal abnormality
•Concomitant or expected treatment with inhaled nitric oxide
•Any infant with fragile skin where EIT belt placement or TBS placement may damage the skin.